Human Skin Mast Cells Research Articles

Infection of in vivo differentiated human mast cells with hantaviruses

Increased vascular permeability is a key feature of the pathological symptoms caused by hantaviruses. Here, we analysed the interaction between hantaviruses and mast cells, which regulate vascular homeostasis. In highly purified human skin mast cells increasing amounts of Hantaan (HTNV) and, to a lower extent, Prospect Hill (PHV) virions were produced. Replication was confirmed by the production of viral plus-strand RNA as determined by a virus strand-specific RT-PCR. PHV but not HTNV elicited early expression of beta interferon, MxA, ISG15 and CCL5 consistent to studies with other cell types. The data demonstrate that mature mast cells are permissive to infection with hantaviruses. This interaction might contribute to the development of vascular leakage syndrome.

Expression and functionality of proteinase-activated receptors (PARs) on primary human lung mast cells

Introduction: Mast cell (MC) activation is known to promote anaphylactic reactions as well as the development of allergic and non-allergic inflammatory diseases. Apart from reacting to cross-linking of IgE-receptors by allergen, MC can be activated through a variety of alternative mechanisms. There is initial evidence that also proteinase-activated receptors (PARs) could have a role. PARs belong to the G protein-coupled receptor family and comprise four members (PAR-1 to 4). While the expression of functional PAR-2 on human skin MC as well as mRNA expression for PAR-1, PAR-3 and PAR-4 has been reported recently, so far nothing is known about the expression and the potential function(s) of PARs on primary human lung MC. We, therefore, isolated primary MC from human lung tissue and examined the expression and functionality of PARs. Methods: Human primary lung MC were isolated by a three-step procedure including enzymatic lung tissue digestion, density gradient centrifugation, and immunoaffinity purification by using anti-CD117 and anti-CD203c antibodies. Results: Using >95% pure MC we could show mRNA expression for PAR-1, PAR-2, PAR-3 and PAR-4. PAR-specific antibodies revealed the expression of PAR-1 on the cell membrane and of PAR-2 being located intracellularly, whereas PAR-3 and PAR-4 were not detected by the antibodies used. PAR-activating peptides (PAR-APs) selective for PAR-1, PAR-2 and PAR-4 were able to induce elevation of intracellular free Ca2+-ion concentration ([Ca2+]i) in these cells. Moreover, PAR-1-AP and PAR-4-AP, but not PAR-2-AP stimulated MC degranulation as determined by the release of β-hexosaminidase. Stimulation with PAR-1-selective ligands led to downregulation of PAR-1. Looking for the effect of natural PAR-ligands, we tested proteinases from blood (thrombin, factor Xa, plasmin), from leukocytes (elastase, cathepsin G, proteinase 3), trypsin, and also MC-specific proteinases (chymase, tryptase). Out of these, only thrombin (PAR-1, and -4-ligand) and trypsin (PAR-2-ligand) induced Ca2+-signalling whereas none induced degranulation. Discussion: Our results demonstrate the functional expression of PAR-1, PAR-2 and PAR-4 in primary human lung MC. However, the induction of Ca2+-signalling in the absence of a degranulation response to thrombin and trypsin suggests, that natural ligands for these receptors may act differently from synthetic APs and moreover are likely to stimulate alternative functions in human primary lung MC.

The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models

Miltefosine is currently marketed for treatment of skin metastasis of breast cancer and leishmaniasis. The mechanism of action is not fully understood, however, miltefosine is considered to be a prototype lipid raft modulator. The compound was shown to inhibit anti-IgE induced histamine release from human skin mast cells. After topical treatment it reduced skin reaction in allergic human volunteers undergoing a skin prick test. The aim of this study was to test whether miltefosine could also modify T-cell signalling and whether the drug may be useful for the treatment of atopic dermatitis. Miltefosine (20 µM) inhibited T-cell proliferation by > 50% in the mixed leukocyte test. In the toluene diisocyanate induced ear swelling test, miltefosine, administered topically as 2 and 6% solution or orally, attenuated ear swelling reaching 70% of the effect of dexamethasone at 100 mg/kg p.o. ( P < 0.01). The ear tissue content of the cytokines IL1ß, IL4 and IL6 was also reduced reaching 56% or 52% reduction of IL1ß ( P < 0.01) after 2% topical or 100 mg/kg p.o. Miltefosine significantly attenuated the allergic sensitization in the model of ovalbumin induced delayed - type hypersensitivity in mice. In a model of toluene diisocyanate induced scratching a significant ( P = 0.0047) reduction of scratching from 47 to 6 bouts was achieved with 100 mg/kg p.o. The data indicate that miltefosine modulates T-cell function in models for Th1 and Th2 related activity. This profile opens up the possibility for the treatment of T-cell related allergic diseases with a novel class of lipid raft modulator drugs such as miltefosine.

A Novel Nanomedicine Platform for Controlling Mast Cell Activation (36.14)

Abstract Mast cells play a critical role in the initiation and propagation of several inflammatory diseases and are well known for their function in the allergic response. Fullerenes are a class of novel carbon allotropes with a wide variety of applications in biotechnology and medicine. Here we use a fullerene-based chemistry platform to develop and test several different fullerene derivatives to evaluate on cellular viability, anti-IgE receptor-mediated degranulation, and cytokine release from human skin mast cells (MC). The biological response depended on the properties of the addition group; some fullerene structures were effective inhibitors of degranulation and also blocked cytokine release, while others were ineffective. None were toxic to the cells using concentrations up to 100 µg/ml. Further, we demonstrate that mitochondrial membrane potential (MMP) closely paralleled IgE-mediated SMC degranulatory responses and this response was greatly inhibited by fullerene pre-incubation. Additionally, the fullerene inhibition was due to the inhibition of FcεRI-mediated MAP kinase activation. These findings suggest the biological properties of fullerene derivatives depends on the derivatization of the carbon cage which can be manipulated to compounds which may control those diseases associated with MC activation.

Human mast cells express leptin and leptin receptors

Mast cells are immune cells that produce and secrete a variety of mediators and cytokines that influence various inflammatory and immune processes. Leptin is a cytokine regulating metabolic, endocrine as well as immune functions via the leptin receptor which is expressed by many immune cells. However, there are no data about leptin receptor expression in mast cells. Immunohistochemical and immunofluorescent double stainings showed the expression of leptin and leptin receptors in mast cells in human skin and several parts of the respiratory, gastrointestinal and urogenital tract. Leptin was expressed in mast cells expressing the classification marker chymase, whereas a variable expression was observed in tryptase positive mast cells. For leptin receptors, the expression pattern was tissue dependent and not related to tryptase or chymase expression. Our results demonstrate the expression of leptin and leptin receptors on mast cells, suggesting paracrine and/or autocrine immunomodulatory effects of leptin on mast cells.

Association of TNF-α promoter polymorphisms with aspirin-induced urticaria

Although the pathogenesis of aspirin-induced urticaria (AIU) is not fully understood, mast cell activation has been noted in patients with AIU. Tumour necrosis factor (TNF)-alpha, a potent pro-inflammatory cytokine, is released by human skin mast cells and other inflammatory cells in patients with urticaria. To investigate the role of TNF-alpha promoter polymorphisms in the development of AIU, we performed an association study of TNF-alpha promoter polymorphisms with AIU phenotype. Two hundred thirty-nine patients with AIU consisting of 120 patients with aspirin intolerant chronic urticaria (AICU) and 119 with aspirin-intolerant acute urticaria (AIAU), and 524 normal controls were enrolled. AIU was confirmed by oral aspirin challenge test. Five SNPs in the TNF-alpha gene (-1031T>C, -863C>A, -857C>T, -308G>A, -238G>A) were genotyped by a single-base extension method. Haplotype analyses were done. The genotype frequencies of TNF-1031T>C and TNF-863C>A were significantly higher in the AIU patients than in the normal controls in both co-dominant (P = 0.014, P = 0.007) and dominant (P = 0.007, P = 0.004) models. The frequency of TNF-ht2[CACGG] containing a genotype in the AIU group was significantly higher in the normal controls with both co-dominant (P = 0.004, Pc = 0.02) and dominant models (P = 0.002, Pc = 0.01). These findings suggest that the two promoter polymorphisms of TNF-alpha at -1031T>C and -863C>A may contribute to the development of AIU.

TGF-β1 Attenuates Mediator Release and De Novo Kit Expression by Human Skin Mast Cells through a Smad-Dependent Pathway

TGF-beta has pleiotropic effects on many cell types at different stages of their development, including mast cells. The present study examines the effects of TGF-beta on human skin mast cells of the MC(TC) type. The expression of TGF-beta receptors (TGF-R) was verified at the mRNA and protein levels for TGF-RI and TGF-RII, and at the mRNA level for accessory molecules beta-glycan and endoglin. TGF-beta did not affect mast cell viability after 1 wk at concentrations < or = 10 ng/ml, but at 50 ng/ml caused significant cell death. TGF-beta inhibited surface and total expression of Kit in a dose-dependent manner, whereas the surface expression of Fc epsilonRI, Fc gammaRI, and Fc gammaRII was not affected. TGF-beta inhibited degranulation and cytokine production, but not PGD(2) production. TGF-beta diminished surface Kit expression through a TGF-RI kinase/Smad-dependent pathway by inhibiting new synthesis of Kit protein, which became evident following internalization and degradation of Kit after mast cells were exposed to the Kit ligand, stem cell factor. In contrast, addition of TGF-beta had no discernible effect on surface Kit expression when administered 3 days after stem cell factor, by which time surface Kit levels had returned to baseline. Although both transcription and translation are important for de novo expression of Kit, Kit mRNA levels were not affected by TGF-beta. Therefore, transcription of a gene other than Kit might be involved in Kit expression. Finally, activation of mast cells increased their susceptibility to TGF-beta-mediated apoptosis, a process that might regulate the survival of activated mast cells in vivo.

Pan‐neurotrophin receptor p75NTR expression is strongly induced in lesional atopic mast cells

Neurotrophins such as nerve growth factor or brain-derived neurotrophic factor influence neuronal proliferation and differentiation via the low-affinity pan-neurotrophin receptor p75NTR that may play a pivotal role in linking the immune with the nervous system. Because the precise regulation of p75NTR gene transcription in mast cells under states of allergic inflammation has not been investigated in detail so far, the present studies assessed the gene regulation and expression of this receptor. Transcriptional expression of p75NTR in human skin was studied in isolated cutaneous cells by means of RT-PCR. In situ lesional mast cell p75NTR expression was analysed by immunohistochemistry. The p75NTR mRNA expression was found in isolated human skin mast cells and keratinocytes. Lower mRNA levels were present in fibroblasts and melanocytes but no transcripts were found in endothelial cells. The p75NTR protein expression was found in situ in lesional and non-lesional mast cells. A significantly increased expression of p75NTR protein was found in atopic dermatitis lesional mast cells when compared with control mast cell expression (P<0.05). The demonstration of an increased level of p75NTR gene transcription in lesional mast cells points to an induction of low-affinity neurotrophin receptor sensitivity of mast cells under states of allergic inflammation. Topically administered neurotrophin receptor-modulating compounds may act as anti-inflammatory mediators in cutaneous allergic inflammation.

Generation of Anaphylatoxins by Human β-Tryptase from C3, C4, and C5

Both mast cells and complement participate in innate and acquired immunity. The current study examines whether beta-tryptase, the major protease of human mast cells, can directly generate bioactive complement anaphylatoxins. Important variables included pH, monomeric vs tetrameric forms of beta-tryptase, and the beta-tryptase-activating polyanion. The B12 mAb was used to stabilize beta-tryptase in its monomeric form. C3a and C4a were best generated from C3 and C4, respectively, by monomeric beta-tryptase in the presence of low molecular weight dextran sulfate or heparin at acidic pH. High molecular weight polyanions increased degradation of these anaphylatoxins. C5a was optimally generated from C5 at acidic pH by beta-tryptase monomers in the presence of high molecular weight dextran sulfate and heparin polyanions, but also was produced by beta-tryptase tetramers under these conditions. Mass spectrometry verified that the molecular mass of each anaphylatoxin was correct. Both beta-tryptase-generated C5a and C3a (but not C4a) were potent activators of human skin mast cells. These complement anaphylatoxins also could be generated by beta-tryptase in releasates of activated skin mast cells. Of further biologic interest, beta-tryptase also generated C3a from C3 in human plasma at acidic pH. These results suggest beta-tryptase might generate complement anaphylatoxins in vivo at sites of inflammation, such as the airway of active asthma patients where the pH is acidic and where elevated levels of beta-tryptase and complement anaphylatoxins are detected.

Omalizumab Reverses the Phenotypic and Functional Effects of IgE-Enhanced FcεRI on Human Skin Mast Cells

The dramatic effects of the anti-IgE mAb omalizumab to lower free IgE levels and Fc epsilonRI levels on basophils contrast with more modest clinical effects. Accordingly, whether IgE modulates Fc epsilonRI levels and Fc epsilonRI-dependent mediator release in vitro on human skin mast cells (MC(TC) type) that had matured in vivo is of interest. IgE reversibly enhanced Fc epsilonRI levels on MC(TC) cells in a dose- and time-dependent manner (up-regulation t(1/2) of 4-5 days with 1-3 microg/ml IgE), without affecting cell proliferation. A molar ratio of omalizumab to IgE of 0.9 at baseline prevented receptor up-regulation by 50%, whereas adding omalizumab to MC(TC) cells already with IgE-enhanced Fc epsilonRI levels at molar ratios of 5, 12.5, and 31 reduced Fc epsilonRI levels to baseline with respective t(1/2) values of 8.7, 6.3, and 4.8 days. MC(TC) cells with IgE-enhanced Fc epsilonRI levels were more sensitive to stimulation with a low dose of anti-Fc epsilonRI mAb in terms of degranulation and production of PGD(2), GM-CSF, IL-6, IL-13, and TNF-alpha. Reducing up-regulated Fc epsilonRI levels with omalizumab also reduced mediator release to a low dose of anti-Fc epsilonRI mAb to baseline by 3-4 wk. Thus, reducing free IgE should decrease the hypersensitivity of allergic individuals to low naturally occurring concentrations of allergens.

IgE Reversibly Enhances FcɛRI levels on the Surface of Human Skin Mast Cells and Increases Sensitivity to Low Levels of FcɛRI Cross-Linking

RATIONALE: In humans, serum IgE levels correlate with FcɛRI levels on short-lived peripheral blood basophils. This study examines IgE-dependent FcɛRI expression on long-lived tissue-dispersed human mature mast cells and the effect on mediator release.

The effect of Na+-K+ ATPase inhibition by ouabain on histamine release from human cutaneous mast cells

There are controversial reports on the effect of sodium-potassium adenosine triphosphatase (Na+-K+ ATPase) inhibition on mast cell mediator release. Some of them have indicated that ouabain (strophanthin G), a specific Na+-K+ ATPase inhibitor, inhibited the release, whereas the others have shown that ouabain had no effect or even had a stimulatory effect on the mediator secretion. Most of these studies have utilized animal-derived mast cells. The aim of this study was to determine the effect of Na+-K+ ATPase inhibition on human skin mast cells. Unpurified and purified mast cells were obtained from newborn foreskins and stimulated by calcium ionophore A23187 (1 microM) for 30 min following a 1 hr incubation with various concentrations (10(-4) to 10(-8) M) of ouabain. Histamine release was assayed by enzyme-linked immunosorbent assay (ELISA). The results indicated that ouabain had no significant effect on the non-immunologic histamine release from human skin mast cells, in vitro. Na+-K+ ATPase inhibition by ouabain had no significant effect on the non-immunologic histamine release from human cutaneous mast cells and suggested differences between human and animal mast cells.

Viewpoint 5

Viewpoint 5

Human Mast Cells in the Neurohormonal Network: Expression of POMC, Detection of Precursor Proteases, and Evidence for IgE-Dependent Secretion of α-MSH

Human mast cells have been shown to release histamine in response to the neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH), but it is unknown whether these cells express proopiomelanocortin (POMC) or POMC-derived peptides. We therefore examined highly purified human skin mast cells and a leukemic mast cell line-1 (HMC-1) for their ability to express POMC and members of the prohormone convertase (PC) family known to process POMC. Furthermore, we investigated whether these cells store and secrete alpha-MSH. Reverse transcriptase-PCR (RT-PCR) analysis revealed that both skin mast cells and HMC-1 cells express POMC mRNA and protein. Expression of the POMC gene at the RNA level in HMC-1 cells could be confirmed by Northern blotting. Transcripts for both PC1 and furin convertase were detectable in skin-derived mast cells and HMC-1 cells, as shown by RT-PCR. In contrast, PC2 transcripts were detected only in skin mast cells, whereas transcripts for paired basic amino acid converting enzyme 4 (PACE4) were present only in HMC-1 cells. Radioimmunoassays performed on cell lysates and cell culture supernatants from human skin-derived mast cells disclosed immunoreactive amounts of alpha-MSH in both fractions. Stimulation with an anti-IgE antibody significantly reduced intracellular alpha-MSH and increased extracellular levels, indicating IgE-mediated secretion of this neuropeptide. Our findings show that human mast cells are active players in the cutaneous POMC system. Mast cell-derived alpha-MSH may contribute to cutaneous hyperpigmentation as seen in patients with urticaria pigmentosa. Moreover, IgE-dependent release of alpha-MSH suggests an immunomodulatory role of this neurohormone during inflammatory and allergic reactions of the skin.

Human mast cells in the neurohormonal network: expression of POMC, detection of precursor proteases, and evidence for IgE‐dependent secretion of alpha‐MSH

Human mast cells have been shown to release histamine in response to the neuropeptide α‐melanocyte‐stimulating hormone (alpha‐MSH), but it is unknown whether these cells express proopiomelanocortin (POMC) or POMC‐derived peptides. We therefore examined highly purified human skin mast cells and a leukemic mast cell line (HMC‐1) for their ability to express POMC and members of the prohormone convertase (PC) family known to process POMC. Furthermore, we investigated whether these cells store and secrete α‐MSH. RT‐PCR analysis revealed that both skin mast cells and HMC‐1 cells express POMC mRNA and protein. Expression of the POMC gene at the RNA level in HMC‐1 cells could be confirmed by Northern blotting. Transcripts for both PC1 and furin convertase were detectable in skin‐derived mast cells and HMC‐1 cells, as shown by RT‐PCR. In contrast, PC2 transcripts were detected only in skin mast cells, while transcripts for PACE4 were present only in HMC‐1 cells. Radioimmunoassays performed on cell lysates and cell culture supernatants from human skin‐derived mast cells disclosed immunoreactive amounts of alpha‐MSH in both fractions. Stimulation with an anti‐IgE antibody significantly reduced intracellular alpha‐MSH and increased extracellular levels, indicating IgE‐mediated secretion of this neuropeptide. Our findings show that human mast cells are active players in the cutaneous POMC system. Mast cell‐derived alpha‐MSH may contribute to cutaneous hyperpigmentation as seen in patients with urticaria pigmentosa. Moreover, IgE‐dependent release of alpha‐MSH suggests an immunomodulatory role of this neurohormone during inflammatory and allergic reactions of the skin.

FcγRIIa, Not FcγRIIb, Is Constitutively and Functionally Expressed on Skin-Derived Human Mast Cells

The expression of FcgammaR by human skin-derived mast cells of the MC(TC) type was determined in the current study. Expression of mRNA was analyzed with microarray gene chips and RT-PCR; protein by Western blotting and flow cytometry; function by release of beta-hexosaminidase, PGD(2), leukotriene C(4) (LTC(4)), IL-5, IL-6, IL-13, GM-CSF, and TNF-alpha. FcgammaRIIa was consistently detected along with FcepsilonRI at the mRNA and protein levels; FcgammaRIIc was sometimes detected only by RT-PCR; but FcgammaRIIb, FcgammaRI, and FcgammaRIII mRNA and protein were not detected. FcgammaRIIa-specific mAb caused skin MC(TC) cells to degranulate and secrete PGD(2), LTC(4), GM-CSF, IL-5, IL-6, IL-13, and TNF-alpha in a dose-dependent fashion. FcepsilonRI-specific mAb caused similar amounts of each mediator to be released with the exception of LTC(4), which was not released by this agonist. Simultaneous but independent cross-linking of FcepsilonRI and FcgammaRIIa did not substantially alter mediator release above or below levels observed with each agent alone. Skin MC(TC) cells sensitized with dust-mite-specific IgE and IgG, when coaggregated by Der p2, exhibited enhanced degranulation compared with sensitization with either IgE or IgG alone. These results extend the known capabilities of human skin mast cells to respond to IgG as well as IgE-mediated signals.

Functional Characterization and Expression Analysis of the Proteinase-Activated Receptor-2 in Human Cutaneous Mast Cells

Proteinase-activated receptor-2 (PAR2) belongs to a new G protein-coupled receptor subfamily activated by serine proteinases. PAR2 has been demonstrated to play a role during inflammation and immune response in different tissues including the skin. We examined whether PAR2 is functionally expressed by cutaneous human primary skin mast cells (HPMC) and the human mast cell line 1 (HMC-1). Reverse transcription-polymerase chain reaction and FACS analysis show expression of PAR2 both at the RNA and protein level. HPMCs and HMC-1 also express PAR1, PAR3, and PAR4. Ca-mobilization studies demonstrate functional PAR2 expressed by human skin mast cells, as shown by natural and synthetic PAR2 agonists. PAR2 agonists induced histamine release from HPMC indicating a role of PAR2 in regulating inflammatory and immune responses by skin mast cells. Double-immunofluorescence staining reveals colocalization of PAR2 with tryptase in the majority of human skin mast cells. In conclusion, trypsin and tryptase as well as specific agonists for PAR2 were able to induce Ca2+ mobilization in HPMCs, and agonists of PAR2 induce the release of histamine from these cells. Thus, PAR2 may be an important regulator of skin mast cell function during cutaneous inflammation and hypersensitivity.

Mast cells and neutrophils proteolytically activate chemokine precursor CTAP-III and are subject to counterregulation by PF-4 through inhibition of chymase and cathepsin G

AbstractThe CXC chemokines platelet factor 4 (PF-4/CXCL4) and connective tissue-activating peptide III (CTAP-III) are released by activated human platelets in micromolar concentrations. So far, neutrophils have been recognized to cleave the precursor CTAP-III to form the active chemokine neutrophil-activating peptide 2 (NAP-2/CXCL7) through limited proteolysis by membrane-associated cathepsin G. Here we show for the first time that activated human skin mast cells (MCs) convert CTAP-III into biologically active NAP-2 through proteolytic cleavage by released chymase. A direct comparison on a cell number basis revealed that unstimulated MCs exceed the CTAP-III–processing potency of neutrophils about 30-fold, whereas MCs activated by IgE cross-linking exhibit even 1000-fold higher CTAP-III–processing capacity than fMLP-stimulated neutrophils. Intriguingly, PF-4 counteracted MC- as well as neutrophil-mediated NAP-2 generation at physiologically relevant concentrations. Addressing the underlying mechanism, we obtained evidence that PF-4 acts as an inhibitor of the CTAP-III–processing enzymes cathepsin G and chymase without becoming cleaved itself as a competitive substrate. Because cleavage of the CTAP-III–unrelated substrate substance P was also affected by PF-4, our results suggest a regulatory role for PF-4 not only in NAP-2 generation but also in neutrophil- and MC-mediated processing of other physiologically relevant inflammatory mediators.

Mast cells in photodamaged skin: what is their role in skin cancer?

In this review, changes that we have observed in the prevalence of mast cells in human sun-exposed skin, and their potential immunoregulatory role, are discussed. More specifically, in a study of Australian volunteers, the prevalence of dermal mast cells was increased in back-of-hand skin, anecdotally the most sun-exposed site of the body, but not in skin from buttock, inner arm or shoulder. By histological analysis of back-of-hand skin, there was a significant correlation between dermal mast cell prevalence and elastin content suggesting increased mast cell prevalence with photodamage. We hypothesised that these mast cells were immunomodulatory upon activation by sun exposure. However, no link was found between dermal mast cell prevalence in hand skin and the presence of basal cell carcinomas. Finally, we discuss other roles for increased numbers of mast cells in UV-exposed photodamaged skin.

Divergent effects of the major mast cell products histamine, tryptase and TNF-alpha on human fibroblast behaviour.

Fibroblast proliferation is a key process in tissue remodeling and mast cells (MCs) are thought to play a crucial role. Having established that the three major MC products, tryptase, histamine and TNF-alpha (TNF) are normally present in human skin MCs, which are in close proximity to dermal fibroblasts, we studied their individual effects on cell cycle-controlled human dermal fibroblasts (HFFF2). These cells express receptors (H1, PAR2, TNFR1/2) for the major MC mediators, but only tryptase or a PAR2 agonist peptide stimulated proliferation and gene expression. TNF was antimitotic, and histamine, while elevating intracellular Ca2+ levels at high concentrations, did not affect proliferation. We conclude that MC products but also composition and numbers of respective receptors on fibroblasts are crucially responsible for fibroproliferative events.